hMSCs: A Secret(ome) Weapon Against ARDS
Authored by Mayasari Lim, PhD, Jonathan Carson, PhD, and Jon A. Rowley, PhD, RoosterBio, Inc. Some research suggests that ARDS might be treatable with the secretome of MSCs. Scientists and ... More
Clinical Trials
“Honey, We Shrunk the Curve!”
By Jonathan Carson, PhD and Jon A. Rowley, PhD, with acknowledgement to scientists who sounded the alarm like Dr. Liz Specht and to all health workers on the front lines. ... More
Can MSCs Treat Patients with COVID-19?
Authored by Mayasari Lim | West Coast and APAC lead for RoosterBio Amidst the scramble and panic-buying that some of us are experiencing, several treatments to combat this novel ... More
Scalable MSC Manufacturing Matters in a Rapid Response to COVID-19
Authored by: Jon Carson, Iain Farrance, John Getz, and Jon A. Rowley, RoosterBio, Inc. On 31-December-2019, Chinese officials alerted the World Health Organization of an outbreak of pneumonia cases in ... More
Quality Begins at Inception
Authored by: Kathy Williams, Vice President of Quality Assurance/Regulatory Affairs and Caitlin Hansen, Director of Quality Control RoosterBio Quality Excellence: we nurture a hard-working innovative culture where quality begins at ... More
The Use of Animal Serum in the Clinical Translation of hMSCs
Human mesenchymal stem or stromal cells (hMSCs) are an integral part of cell-based therapeutics, with over 400 clinical trials recently completed or in progress using hMSCs. As more research teams ... More
How Quickly are Cell-based Products Really Developing? Thoughts from the IBC Cell Therapy Bioprocessing Conference
Last week was the 4th Annual IBC Cell Therapy Bioprocessing Conference. IBC (home of the BioProcess International conference) was the first conference organizer to dedicate a focused meeting on Cell Therapy Manufacturing Technologies 4 ... More